Tag: risk

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

Cloud mining pioneer adds support for XRP and DOGE to help investors generate daily earnings without hardware or technical skills

U.S.-Based Brand Gunner Gear, LLC Updates Tac Wallet Pro Site to Showcase RFID-Blocking Features, Minimalist Design, and Tactical Construction for 2025 Everyday Carry Needs

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”) announced today management fee reductions, change in portfolio manager and change in risk ratings for certain of its mutual funds.  Details of these changes are set out below.

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on July 15, 2025 to holders of Common Shares of record on June 30, 2025.

The Sleep Connection Grounding Pillowcase now features enhanced product details highlighting silver-thread grounding technology, natural materials, and ease of use for wellness-focused routines

CALGARY, Alberta, June 23, 2025 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX:TRP) (NYSE:TRP) (TC Energy or the Company) today announced that 104,778 of its 9,997,177 fixed rate Cumulative Redeemable First Preferred Shares, Series 3 (Series 3 Shares) have been elected for conversion on June 30, 2025, on a one-for-one basis, into floating rate Cumulative Redeemable First Preferred Shares, Series 4 (Series 4 Shares); and 1,822,829 of its 4,002,823 Series 4 Shares have been elected for conversion, on a one-for-one basis, into Series 3 Shares.

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET.